Related Experiment Video
Updated: Jan 18, 2026

09:15
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
3.9K
Administration of high-dose interleukin-2 in a 2-year-old with metastatic melanoma
M Brooke Bernhardt1, M John Hicks, Alberto S Pappo
1Department of Pharmacy, Texas Children's Hospital, Houston, Texas 77030, USA. mbbernha@texaschildrens.org
Pediatric Blood & Cancer
|September 5, 2009
Abstract:
Malignant melanoma is rare in pediatrics, and therapies for patients with disseminated disease have not been well studied. This report describes our experience with the use of high-dose interleukin 2 (aldesleukin, IL-2) in a 2-year-old child with metastatic melanoma and describes our approach for the administration of this agent to young patients.

